- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Insights from the COORDINATE-Diabetes Trial
A panel of experts explores the objectives and design of the COORDINATE-Diabetes trial, discussing its potential impact on the treatment paradigm for diabetes management.
EP: 1.The Impact of CRM Diseases in the US: Burden, Prevalence, and Obesity
EP: 2.Strategies for Prevention and Screening of CRM Conditions
EP: 3.The Link Between Obesity and CRM Conditions
EP: 4.Challenges in Managing Co-Morbid CRM Conditions
EP: 5.Contemporary Guidelines for CRM Conditions
EP: 6.Reasons for Low Adherence to Guidelines for CRM Conditions
EP: 7.Overcoming Barriers to Prescribing First-Line Medications for CRM Conditions
EP: 8.Educational Initiatives to Enhance Guideline Adherence in CRM
EP: 9.Addressing Gaps in CKD, T2D, and CVD Guidelines
EP: 10.Care Coordination for High-Risk CRM Patients
EP: 11.Takeaways from the UH CINEMA Program
EP: 12.Exploring the Kidney-CHAMP Study
EP: 13.Insights from the COORDINATE-Diabetes Trial
EP: 14.Coordinating Initiatives to Enhance CRM Care
EP: 15.Implementing CRM Learnings and Utilization of Telehealth
Video content above is prompted by the following:
- Tell us about the COORDINATE-Diabetes trial.
- What were the objectives of COORDINATE-Diabetes and how was the trial designed?
- What interventions were provided?
- What were the results of the study?
- What are future opportunities to improve CRM care based on this trial?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More
